Bayer’s $7.25 Billion Settlement Approved in Cancer Lawsuits Over Roundup Weed Killer

Bayer’s $7.25 Billion Settlement Approved in Cancer Lawsuits Over Roundup Weed Killer

Can a widely used weed killer cause cancer? This question has been at the center of years of legal battles involving Roundup, a popular herbicide made by Monsanto, a company owned by Bayer. Thousands of people have claimed that exposure to the product caused them to develop non-Hodgkin lymphoma, a type of blood cancer.

On November 20, Bayer announced that Missouri state court granted final approval to a nationwide class settlement covering claims that exposure to Roundup caused non-Hodgkin lymphoma (NHL). The agreement establishes a long-term claims program for people who already have an NHL diagnosis and those diagnosed within a specified period.

Monsanto will fund the settlement through annual payments totaling up to $7.25 billion. The court’s approval follows a June U.S. Supreme Court ruling on whether plaintiffs could pursue state law claims over the absence of a cancer warning on Roundup’s label. The final approval order remains subject to appeal.

Bill Anderson, CEO of Bayer, said:

”The Court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup™ litigation.”

What Is Roundup?

Roundup is a brand of weed killers. The product at issue in Monsanto v. Durnell is a glyphosate-based herbicide made by Monsanto and regulated by the U.S. Environmental Protection Agency. John Durnell alleged that exposure to Roundup caused his non-Hodgkin lymphoma and that Monsanto should have included a cancer warning on the product label.

Bayer maintains that glyphosate-based herbicides can be used safely and are not carcinogenic, citing regulatory assessments. The nationwide settlement establishes a process for resolving eligible non-Hodgkin lymphoma claims involving alleged Roundup exposure. Monsanto did not admit liability or wrongdoing under the agreement.

Who Qualifies for the Roundup Settlement

The settlement covers people who allege that they were exposed to Roundup before February 17, 2026, and meet one of two medical diagnosis criteria. The same exposure cutoff applies to both groups.

  • People with an existing diagnosis must already have a medical diagnosis of non-Hodgkin lymphoma.
  • People diagnosed in the future must receive a medical diagnosis of non-Hodgkin lymphoma before the end of the 16-year period following the agreement’s effective date.

The claims program covers eligible NHL injury claims regardless of the legal theory behind them. The settlement agreement contains no admission of liability or wrongdoing by Monsanto. Bayer said Monsanto pursued the agreement to limit its exposure to both pending litigation and claims that could arise from future diagnoses.

How Monsanto Will Fund the Claims Program

Monsanto will make capped annual payments that decline over a period of up to 21 years. The $7.25 billion maximum includes payments the company has already made. The 21-year schedule governs Monsanto’s contributions to the settlement, while the 16-year period governs eligibility for people diagnosed after the agreement takes effect. Bayer said the payment schedule would allow Monsanto to plan for the costs of resolving claims from both groups.

How the Durnell and Aretino Decisions Fit In

In Monsanto v. Durnell, the U.S. Supreme Court considered a Missouri state law claim alleging that Monsanto should have included a cancer warning on the Roundup label. The Court ruled that federal pesticide law preempted the claim. Bayer described failure to warn as the central theory in the Roundup litigation and said it expects the ruling to bar claims based on that theory, including claims brought by people who opt out of the settlement.

Bayer identified Aretino as the first Roundup case to go to trial after Durnell. The trial court applied the Supreme Court decision to rule that the plaintiffs’ failure-to-warn claims were preempted. Three other claims proceeded to trial, alleging a design defect, fraud, and negligence. The jury returned a unanimous verdict for Monsanto on those claims.

Litigation Outside the Class Settlement

Bayer expects opt-outs to account for a small proportion of current and potential future claims. The company said some people who opt out may pursue their cases in court. According to Bayer, those plaintiffs would need to establish that their claims remain legally viable after Durnell and then prove them in court. Monsanto said it believes its existing provisions are sufficient to cover the remaining litigation.

If the final approval order is appealed, Monsanto would pause further payments under the agreement until all appeals are exhausted. Bayer said it would work with lawyers representing the settlement class to defend the order against any challenge. Monsanto also said it would continue to defend cases outside the settlement and apply the Durnell ruling where relevant. The announcement did not specify a date for the next settlement payment.

You can also read: Bayer Plans $2.2 Billion Ohio Manufacturing Campus to Support Oncology and Cardiorenal Portfolio.

Bayer